Trypanosoma brucei Glycogen Synthase Kinase-3, A Target for Anti-Trypanosomal Drug Development: A Public-Private Partnership to Identify Novel Leads

Background Trypanosoma brucei, the causative agent of Human African Trypanosomiasis (HAT), expresses two proteins with homology to human glycogen synthase kinase 3β (HsGSK-3) designated TbruGSK-3 short and TbruGSK-3 long. TbruGSK-3 short has previously been validated as a potential drug target and since this enzyme has also been pursued as a human drug target, a large number of inhibitors are available for screening against the parasite enzyme. A collaborative industrial/academic partnership facilitated by the World Health Organisation Tropical Diseases Research division (WHO TDR) was initiated to stimulate research aimed at identifying new drugs for treating HAT. Methodology/Principal Findings A subset of over 16,000 inhibitors of HsGSK-3 β from the Pfizer compound collection was screened against the shorter of two orthologues of TbruGSK-3. The resulting active compounds were tested for selectivity versus HsGSK-3β and a panel of human kinases, as well as in vitro anti-trypanosomal activity. Structural analysis of the human and trypanosomal enzymes was also performed. Conclusions/Significance We identified potent and selective compounds representing potential attractive starting points for a drug discovery program. Structural analysis of the human and trypanosomal enzymes also revealed hypotheses for further improving selectivity of the compounds.

[1]  M. Roussel,et al.  Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. , 1998, Genes & development.

[2]  Simone Sciabola,et al.  High-Throughput Biochemical Kinase Selectivity Assays: Panel Development and Screening Applications , 2009, Journal of biomolecular screening.

[3]  P. Kennedy.  The continuing problem of human African trypanosomiasis (sleeping sickness) , 2008, Annals of neurology.

[4]  Thomas D. Y. Chung,et al.  A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays , 1999, Journal of biomolecular screening.

[5]  M. Dumas,et al.  Treatment of human African trypanosomiasis. , 1983, Bulletin of the World Health Organization.

[6]  M. Dumas,et al.  Treatment perspectives for human African trypanosomiasis , 2003, Fundamental & clinical pharmacology.

[7]  Jeffrey Jie-Lou Liao,et al.  Molecular recognition of protein kinase binding pockets for design of potent and selective kinase inhibitors. , 2007, Journal of medicinal chemistry.

[8]  Hilmar Weinmann,et al.  Drug discovery process for kinase inhibitors. , 2005, Chembiochem : a European journal of chemical biology.

[9]  Dustin J Maly,et al.  Toxoplasma gondii calcium-dependent protein kinase 1 is a target for selective kinase inhibitors , 2010, Nature Structural &Molecular Biology.

[10]  Kozo Nakamura,et al.  GSK-3β Controls Osteogenesis through Regulating Runx2 Activity , 2007, PloS one.

[11]  P. Greengard,et al.  Indirubins Inhibit Glycogen Synthase Kinase-3β and CDK5/P25, Two Protein Kinases Involved in Abnormal Tau Phosphorylation in Alzheimer's Disease , 2001, The Journal of Biological Chemistry.

[12]  Kirk W. Johnson,et al.  Modulation of muscle insulin resistance by selective inhibition of GSK-3 in Zucker diabetic fatty rats. , 2003, American journal of physiology. Endocrinology and metabolism.

[13]  S. Knapp,et al.  Structural characterization of the GSK-3beta active site using selective and non-selective ATP-mimetic inhibitors. , 2003, Journal of molecular biology.

[14]  C. Decaestecker,et al.  In vitro antiprotozoal, antimicrobial and antitumor activity of Pavetta crassipes K. Schum leaf extracts. , 2010, Journal of ethnopharmacology.

[15]  T. Hunter,et al.  The Protein Kinase Complement of the Human Genome , 2002, Science.

[16]  M. Barrett,et al.  Chemotherapy of human African trypanosomiasis. , 2002, Current pharmaceutical design.

[17]  B. Doble,et al.  GSK-3: tricks of the trade for a multi-tasking kinase , 2003, Journal of Cell Science.

[18]  Ana Martínez,et al.  Glycogen synthase kinase 3 (GSK‐3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation , 2002, Medicinal research reviews.

[19]  J. Woodgett,et al.  Requirement for glycogen synthase kinase-3β in cell survival and NF-κB activation , 2000, Nature.

[20]  L. Maes,et al.  Anti-infective potential of natural products: how to develop a stronger in vitro 'proof-of-concept'. , 2006, Journal of ethnopharmacology.

[21]  Hilmar Weinmann Dr. and,et al.  Editorial: Drug Discovery Process for Kinease Inhibitors , 2005 .

[22]  Els Torreele,et al.  Drug development for neglected diseases: a deficient market and a public-health policy failure , 2002, The Lancet.

[23]  Hilmar Weinmann,et al.  Editorial: Drug Discovery Process for Kinease Inhibitors , 2005 .

[24]  Timothy N C Wells,et al.  Glycogen Synthase Kinase 3 Is a Potential Drug Target for African Trypanosomiasis Therapy , 2008, Antimicrobial Agents and Chemotherapy.

[25]  R. Nusse,et al.  β-catenin: a key mediator of Wnt signaling , 1998 .

[26]  H. Eldar-Finkelman,et al.  Long-Term Treatment with Novel Glycogen Synthase Kinase-3 Inhibitor Improves Glucose Homeostasis in ob/ob Mice: Molecular Characterization in Liver and Muscle , 2006, Journal of Pharmacology and Experimental Therapeutics.

[27]  R. Jope,et al.  The glamour and gloom of glycogen synthase kinase-3. , 2004, Trends in biochemical sciences.

[28]  P. Simarro,et al.  Eliminating Human African Trypanosomiasis: Where Do We Stand and What Comes Next> , 2008, PLoS medicine.

[29]  C. Naula,et al.  Protein kinases as drug targets in trypanosomes and Leishmania. , 2005, Biochimica et biophysica acta.

[30]  R. Moon,et al.  The axis-inducing activity, stability, and subcellular distribution of beta-catenin is regulated in Xenopus embryos by glycogen synthase kinase 3. , 1996, Genes & development.

[31]  C. Doerig.  Protein kinases as targets for anti-parasitic chemotherapy. , 2004, Biochimica et Biophysica Acta.

[32]  G L Snyder,et al.  Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors? , 2001, The Journal of biological chemistry.

[33]  M. Barrett,et al.  Kynurenine pathway inhibition reduces central nervous system inflammation in a model of human African trypanosomiasis , 2009, Brain : a journal of neurology.